Comprehensive genotyping of the C9orf72 hexanucleotide repeat region in 2095 ALS samples from the NINDS collection using a two-mode, long-read PCR assay.


Journal

Amyotrophic lateral sclerosis & frontotemporal degeneration
ISSN: 2167-9223
Titre abrégé: Amyotroph Lateral Scler Frontotemporal Degener
Pays: England
ID NLM: 101587185

Informations de publication

Date de publication:
02 2019
Historique:
pubmed: 16 11 2018
medline: 11 4 2020
entrez: 16 11 2018
Statut: ppublish

Résumé

Expansion of the G A single-tube 3-primer PCR assay mode, resolved using capillary electrophoresis, was used for sizing up to 145 repeats with single-repeat accuracy, for detecting expansions irrespective of their overall size, and for flagging confounding 3' sequence variations (SVs). A modified two-primer PCR mode, resolved via agarose gel electrophoresis, provided further size information for hyper-expanded samples (>145 repeats) up to ∼5.8 kb amplicons (∼950 G Within the evaluated cohort, 177 (8.4%) samples were expanded, with 175 (99%) samples being hyper-expanded. 3'-SVs were identified in 64 (3.1%) samples, and were most common in expanded alleles. Genotypes of all 606 (29%) homozygous samples were confirmed using an orthogonal PCR assay. This study and PCR method may improve and standardize molecular characterization of the C9orf72 locus, and have the potential to inform phenotype-genotype correlations and therapeutic development in ALS/FTD.

Identifiants

pubmed: 30430876
doi: 10.1080/21678421.2018.1522353
pmc: PMC6513680
mid: NIHMS1520680
doi:

Substances chimiques

C9orf72 Protein 0
C9orf72 protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

107-114

Subventions

Organisme : NINDS NIH HHS
ID : R44 NS089423
Pays : United States

Références

Sci Transl Med. 2013 Oct 23;5(208):208ra149
pubmed: 24154603
Neurobiol Aging. 2015 Mar;36(3):1601.e1-5
pubmed: 25595499
Neuron. 2016 May 4;90(3):535-50
pubmed: 27112497
Mol Cell Probes. 2016 Aug;30(4):218-224
pubmed: 27288208
Acta Neuropathol. 2017 Aug;134(2):271-279
pubmed: 28439722
Nature. 2015 Sep 3;525(7567):56-61
pubmed: 26308891
PLoS One. 2013;8(2):e56899
pubmed: 23437264
Neurology. 2012 Jul 31;79(5):482-3
pubmed: 22815561
Arch Neurol. 2012 Dec;69(12):1583-90
pubmed: 22964832
J Mol Diagn. 2010 Sep;12(5):589-600
pubmed: 20616364
Hum Mutat. 2013 Feb;34(2):363-73
pubmed: 23111906
Neuron. 2011 Oct 20;72(2):257-68
pubmed: 21944779
Am J Med Genet A. 2009 Jul;149A(7):1365-74
pubmed: 19514047
Mol Cell Probes. 2017 Apr;32:60-64
pubmed: 27765650
Lancet Neurol. 2012 Apr;11(4):323-30
pubmed: 22406228
Neuron. 2013 Oct 16;80(2):415-28
pubmed: 24139042
Neuron. 2011 Oct 20;72(2):245-56
pubmed: 21944778
Genet Med. 2014 Dec;16(12):e2
pubmed: 25356969
J Med Genet. 2014 Jun;51(6):419-24
pubmed: 24706941
Toxicol Mech Methods. 2018 Mar;28(3):157-166
pubmed: 28849708
Hum Mol Genet. 2014 Feb 1;23(3):749-54
pubmed: 24057670
J Alzheimers Dis. 2015;45(1):319
pubmed: 25737153
Am J Hum Genet. 2013 Mar 7;92(3):345-53
pubmed: 23434116
Neurology. 2014 Nov 18;83(21):1906-13
pubmed: 25326098
Neurology. 2009 Feb 10;72(6):490-7
pubmed: 19020295
Genet Med. 2012 Aug;14(8):729-36
pubmed: 22498846
Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3-4):256-264
pubmed: 27936955
Am J Hum Genet. 2015 Jun 4;96(6):962-70
pubmed: 26004200
Mol Cell. 2017 Nov 2;68(3):479-490.e5
pubmed: 29056323
Clin Chem. 2010 Mar;56(3):399-408
pubmed: 20056738
Neurology. 1999 Nov 10;53(8):1854-7
pubmed: 10563639

Auteurs

Eran Bram (E)

a Asuragen, Inc , Austin , TX , USA.

Kamyab Javanmardi (K)

a Asuragen, Inc , Austin , TX , USA.

Kimberly Nicholson (K)

a Asuragen, Inc , Austin , TX , USA.

Kristen Culp (K)

a Asuragen, Inc , Austin , TX , USA.

Julie R Thibert (JR)

a Asuragen, Inc , Austin , TX , USA.

Jon Kemppainen (J)

a Asuragen, Inc , Austin , TX , USA.

Vivian Le (V)

a Asuragen, Inc , Austin , TX , USA.

Annette Schlageter (A)

a Asuragen, Inc , Austin , TX , USA.

Andrew Hadd (A)

a Asuragen, Inc , Austin , TX , USA.

Gary J Latham (GJ)

a Asuragen, Inc , Austin , TX , USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH